College of Medical Laboratory Science, Guilin Medical University, Guangxi, China.
Elife. 2024 Oct 15;13:RP95678. doi: 10.7554/eLife.95678.
Current cancer treatment strategies continue to face significant challenges, primarily due to tumor relapse, drug resistance, and low treatment efficiency. These issues arise because certain tumor cells adapt to the host immune microenvironment and evade the immune system. This study presents a new cancer immunotherapy strategy using serum-based antibodies from mice exposed to mouse cutaneous squamous cell carcinoma (mCSCC). The experiment was conducted in three stages. In the first stage, mCSCC cells were isolated and expanded cultured from DMBA/TPA-induced mCSCC. In the second stage, these expanded tumor cells were injected into healthy mice to stimulate the production of anti-tumor antibodies. In the final stage, therapeutic serum was extracted from these healthy mice and reintroduced into the tumor-bearing mice. An ELISA assay was utilized to analyze the levels of p53, Bcl-xL, NF-κB, and Bax. The results showed that the serum treatment not only reduced tumor volume but also reversed changes in p53, Bcl-xL, NF-κB, and Bax. In conclusion, this study developed a new immunotherapeutic strategy for treating mCSCC. However, further research is needed to fully comprehend the mechanism of this serum treatment.
当前的癌症治疗策略仍然面临着重大挑战，主要是由于肿瘤复发、耐药性和治疗效率低下。这些问题的出现是因为某些肿瘤细胞适应了宿主的免疫微环境，从而逃避了免疫系统的攻击。本研究提出了一种新的癌症免疫治疗策略，即利用接触过小鼠皮肤鳞状细胞癌（mCSCC）的小鼠血清中的抗体进行治疗。该实验分三个阶段进行。在第一阶段，从 DMBA/TPA 诱导的 mCSCC 中分离并扩增培养 mCSCC 细胞。在第二阶段，将这些扩增的肿瘤细胞注射到健康小鼠体内，以刺激抗肿瘤抗体的产生。在最后阶段，从这些健康小鼠中提取治疗性血清并重新引入荷瘤小鼠。采用 ELISA 法分析 p53、Bcl-xL、NF-κB 和 Bax 的水平。结果表明，血清治疗不仅降低了肿瘤体积，而且逆转了 p53、Bcl-xL、NF-κB 和 Bax 的变化。总之，本研究开发了一种治疗 mCSCC 的新免疫治疗策略。然而，需要进一步研究来充分理解这种血清治疗的机制。
